Evidence map›Paper›PMID 37533985›Full record

ArticleHeliyon2023

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report.

Manuel Croix, Guénaëlle Levallet, Nicolas Richard, Claire Bracquemart, Taha Tagmouti, Anne Dompmartin, Diane Kottler, Jean Matthieu L'Orphelin

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Manuel CroixDermatology Department, Caen University Hospital, Avenue Côte-de-Nacre, 14000 Caen, France.
Guénaëlle LevalletFederative Structure of Cyto-Molecular Oncogenetics (SF-MOCAE), CHU de Caen, F-14000 Caen, France.
Nicolas RichardFederative Structure of Cyto-Molecular Oncogenetics (SF-MOCAE), CHU de Caen, F-14000 Caen, France.
Claire BracquemartFederative Structure of Cyto-Molecular Oncogenetics (SF-MOCAE), CHU de Caen, F-14000 Caen, France.
Taha TagmoutiDermatology Department, Caen University Hospital, Avenue Côte-de-Nacre, 14000 Caen, France.
Anne DompmartinDermatology Department, Caen University Hospital, Avenue Côte-de-Nacre, 14000 Caen, France.
Diane KottlerDermatology Department, Caen University Hospital, Avenue Côte-de-Nacre, 14000 Caen, France.
Jean Matthieu L'OrphelinDermatology Department, Caen University Hospital, Avenue Côte-de-Nacre, 14000 Caen, France.
Université de Caen Normandie · FRCentre Hospitalier Universitaire de Caen Normandie · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In metastatic stage, therapeutic approach for malignant melanoma is particularly based on performance status, metastatic sites, and

Indexed as

BRAFMelanomaNon V600 mutantNRASTreatment NGS

Identifiers

PMID37533985
PMCPMC10391937
OpenAlexW4384701376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.